ID   BCR_HUMAN               Reviewed;        1271 AA.
AC   P11274; P78501; Q12842; Q4LE80; Q6NZI3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   12-OCT-2022, entry version 244.
DE   RecName: Full=Breakpoint cluster region protein {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:1657398};
DE   AltName: Full=Renal carcinoma antigen NY-REN-26;
GN   Name=BCR {ECO:0000312|HGNC:HGNC:1014}; Synonyms=BCR1, D22S11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT SER-796.
RX   PubMed=3285291;
RA   Lifshitz B., Fainstein E., Marcelle C., Shtivelman E., Amson R., Gale R.P.,
RA   Canaani E.;
RT   "bcr genes and transcripts.";
RL   Oncogene 2:113-117(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHROMOSOMAL TRANSLOCATION.
RX   PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and regions
RT   involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-796.
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-872, CHROMOSOMAL TRANSLOCATION, INVOLVEMENT
RP   IN CML, AND VARIANT SER-796.
RX   PubMed=3107980; DOI=10.1002/j.1460-2075.1987.tb04727.x;
RA   Hariharan I.K., Adams J.M.;
RT   "cDNA sequence for human bcr, the gene that translocates to the abl
RT   oncogene in chronic myeloid leukaemia.";
RL   EMBO J. 6:115-119(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-693, AND INVOLVEMENT IN CML.
RX   PubMed=3540951; DOI=10.1073/pnas.83.24.9768;
RA   Mes-Masson A.-M., McLaughlin J., Daley G.Q., Paskind M., Witte O.N.;
RT   "Overlapping cDNA clones define the complete coding region for the P210c-
RT   abl gene product associated with chronic myelogenous leukemia cells
RT   containing the Philadelphia chromosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9768-9772(1986).
RN   [6]
RP   ERRATUM OF PUBMED:3540951, AND SEQUENCE REVISION.
RA   Mes-Masson A.M., McLaughlin J., Daley G.Q., Paskind M., Witte O.N.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:2507-2507(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 683-1271 (ISOFORM 1).
RX   PubMed=2989703; DOI=10.1038/315758a0;
RA   Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G.;
RT   "Structural organization of the bcr gene and its role in the Ph'
RT   translocation.";
RL   Nature 315:758-761(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-46 AND 275-426.
RX   PubMed=2263470; DOI=10.1093/nar/18.23.7119;
RA   Zhu Q.S., Heisterkamp N., Groffen J.;
RT   "Unique organization of the human BCR gene promoter.";
RL   Nucleic Acids Res. 18:7119-7125(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-426.
RX   PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P., Dreazen O.,
RA   Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 362-438, AND ALTERNATIVE SPLICING.
RX   PubMed=2915904;
RA   Romero P., Beran M., Shtalrid M., Andersson B., Talpaz M., Blick M.;
RT   "Alternative 5' end of the bcr-abl transcript in chronic myelogenous
RT   leukemia.";
RL   Oncogene 4:93-98(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 670-842, INVOLVEMENT IN CML, AND
RP   VARIANT SER-796.
RX   PubMed=2407300;
RA   Selleri L., von Lindern M., Hermans A., Meijer D., Torelli G., Grosveld G.;
RT   "Chronic myeloid leukemia may be associated with several bcr-abl
RT   transcripts including the acute lymphoid leukemia-type 7 kb transcript.";
RL   Blood 75:1146-1153(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-4.
RX   PubMed=1900918; DOI=10.1128/mcb.11.4.1854-1860.1991;
RA   Shah N.P., Witte O.N., Denny C.T.;
RT   "Characterization of the BCR promoter in Philadelphia chromosome-positive
RT   and -negative cell lines.";
RL   Mol. Cell. Biol. 11:1854-1860(1991).
RN   [13]
RP   FUNCTION.
RX   PubMed=1903516; DOI=10.1038/351400a0;
RA   Diekmann D., Brill S., Garrett M.D., Totty N., Hsuan J., Monfries C.,
RA   Hall C., Lim L., Hall A.;
RT   "Bcr encodes a GTPase-activating protein for p21rac.";
RL   Nature 351:400-402(1991).
RN   [14]
RP   INTERACTION WITH ABL1 SH2-DOMAIN.
RX   PubMed=1712671; DOI=10.1016/0092-8674(91)90148-r;
RA   Pendergast A.M., Muller A.J., Havlik M.H., Maru Y., Witte O.N.;
RT   "BCR sequences essential for transformation by the BCR-ABL oncogene bind to
RT   the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.";
RL   Cell 66:161-171(1991).
RN   [15]
RP   FUNCTION AS PROTEIN KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=1657398; DOI=10.1016/0092-8674(91)90521-y;
RA   Maru Y., Witte O.N.;
RT   "The BCR gene encodes a novel serine/threonine kinase activity within a
RT   single exon.";
RL   Cell 67:459-468(1991).
RN   [16]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=7479768; DOI=10.1073/pnas.92.22.10282;
RA   Chuang T.H., Xu X., Kaartinen V., Heisterkamp N., Groffen J., Bokoch G.M.;
RT   "Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein
RT   family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:10282-10286(1995).
RN   [17]
RP   PHOSPHORYLATION AT TYR-177 BY HCK, MUTAGENESIS OF TYR-177, AND INTERACTION
RP   WITH HCK AND GRB2.
RX   PubMed=9407116; DOI=10.1074/jbc.272.52.33260;
RA   Warmuth M., Bergmann M., Priess A., Hauslmann K., Emmerich B., Hallek M.;
RT   "The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent
RT   mechanism and phosphorylates the Grb2-binding site of Bcr.";
RL   J. Biol. Chem. 272:33260-33270(1997).
RN   [18]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1264, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [20]
RP   INTERACTION WITH FES/FPS; ABL1; PIK3R1 AND GRB2, MUTAGENESIS OF TYR-177,
RP   PHOSPHORYLATION AT TYR-246, AND FUNCTION.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster region
RT   protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent
RT   manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [21]
RP   INTERACTION WITH PDZK1, AND MUTAGENESIS OF 1269-THR--GLU-1271 AND VAL-1271.
RX   PubMed=15494376; DOI=10.1242/jcs.01472;
RA   Malmberg E.K., Andersson C.X., Gentzsch M., Chen J.H., Mengos A., Cui L.,
RA   Hansson G.C., Riordan J.R.;
RT   "Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold
RT   protein PDZK1 and vesicle coat protein Mint3.";
RL   J. Cell Sci. 117:5535-5541(2004).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF ARG-1090 AND ASN-1202.
RX   PubMed=17116687; DOI=10.1128/mcb.00756-06;
RA   Cho Y.J., Cunnick J.M., Yi S.J., Kaartinen V., Groffen J., Heisterkamp N.;
RT   "Abr and Bcr, two homologous Rac GTPase-activating proteins, control
RT   multiple cellular functions of murine macrophages.";
RL   Mol. Cell. Biol. 27:899-911(2007).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-459, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-177; SER-459 AND SER-1264,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-215 AND SER-459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-122; SER-139; SER-202;
RP   SER-215; SER-222; SER-356; SER-377; SER-459; SER-463; SER-473; SER-488;
RP   TYR-554; THR-641; TYR-644; THR-693 AND SER-894, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-459, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 3-72, AND HOMOTETRAMERIZATION.
RX   PubMed=11780146; DOI=10.1038/nsb747;
RA   Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., Kim P.S.;
RT   "Structure of the Bcr-Abl oncoprotein oligomerization domain.";
RL   Nat. Struct. Biol. 9:117-120(2002).
RN   [33]
RP   FUNCTION, INTERACTION WITH DLG4, AND MUTAGENESIS OF VAL-1271.
RX   PubMed=20962234; DOI=10.1523/jneurosci.1711-10.2010;
RA   Oh D., Han S., Seo J., Lee J.R., Choi J., Groffen J., Kim K., Cho Y.S.,
RA   Choi H.S., Shin H., Woo J., Won H., Park S.K., Kim S.Y., Jo J.,
RA   Whitcomb D.J., Cho K., Kim H., Bae Y.C., Heisterkamp N., Choi S.Y., Kim E.;
RT   "Regulation of synaptic Rac1 activity, long-term potentiation maintenance,
RT   and learning and memory by BCR and ABR Rac GTPase-activating proteins.";
RL   J. Neurosci. 30:14134-14144(2010).
RN   [34]
RP   FUNCTION, AND MUTAGENESIS OF 689-ASN-GLU-690.
RX   PubMed=23940119; DOI=10.1083/jcb.201304133;
RA   Dubash A.D., Koetsier J.L., Amargo E.V., Najor N.A., Harmon R.M.,
RA   Green K.J.;
RT   "The GEF Bcr activates RhoA/MAL signaling to promote keratinocyte
RT   differentiation via desmoglein-1.";
RL   J. Cell Biol. 202:653-666(2013).
RN   [35]
RP   INTERACTION WITH SH2D5.
RX   PubMed=25331951; DOI=10.1074/jbc.m114.615112;
RA   Gray E.J., Petsalaki E., James D.A., Bagshaw R.D., Stacey M.M., Rocks O.,
RA   Gingras A.C., Pawson T.;
RT   "src homology 2 domain containing protein 5 (sh2d5) binds the breakpoint
RT   cluster region protein, BCR, and regulates levels of Rac1-GTP.";
RL   J. Biol. Chem. 289:35397-35408(2014).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-400; MET-413; GLU-752; SER-796;
RP   CYS-910; ILE-949; LYS-1037; MET-1091; ALA-1096; GLY-1104; ASN-1106;
RP   THR-1149; LYS-1161; GLU-1187; MET-1189; GLY-1204 AND ARG-1235.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein with a unique structure having two opposing
CC       regulatory activities toward small GTP-binding proteins. The C-terminus
CC       is a GTPase-activating protein (GAP) domain which stimulates GTP
CC       hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of
CC       GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the
CC       active GTP-bound form (PubMed:7479768, PubMed:1903516,
CC       PubMed:17116687). The central Dbl homology (DH) domain functions as
CC       guanine nucleotide exchange factor (GEF) that modulates the GTPases
CC       CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1
CC       from the GDP-bound to the GTP-bound form (PubMed:7479768,
CC       PubMed:23940119). The amino terminus contains an intrinsic kinase
CC       activity (PubMed:1657398). Functions as an important negative regulator
CC       of neuronal RAC1 activity (By similarity). Regulates macrophage
CC       functions such as CSF1-directed motility and phagocytosis through the
CC       modulation of RAC1 activity (PubMed:17116687). Plays a major role as a
CC       RHOA GEF in keratinocytes being involved in focal adhesion formation
CC       and keratinocyte differentiation (PubMed:23940119).
CC       {ECO:0000250|UniProtKB:Q6PAJ1, ECO:0000269|PubMed:1657398,
CC       ECO:0000269|PubMed:17116687, ECO:0000269|PubMed:1903516,
CC       ECO:0000269|PubMed:23940119, ECO:0000269|PubMed:7479768}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:1657398};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:1657398};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:1657398};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:1657398};
CC   -!- SUBUNIT: Homotetramer. Interacts with PDZK1 (PubMed:15494376). May
CC       interact with CCPG1 (By similarity). Interacts with FES/FPS, ABL1,
CC       PIK3R1 and GRB2 (PubMed:15302586, PubMed:1712671, PubMed:9407116).
CC       Interacts with HCK (PubMed:9407116). Interacts with SH2D5
CC       (PubMed:25331951). Interacts with DLG4 (PubMed:20962234).
CC       {ECO:0000250|UniProtKB:Q6PAJ1, ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:15494376, ECO:0000269|PubMed:1712671,
CC       ECO:0000269|PubMed:20962234, ECO:0000269|PubMed:25331951,
CC       ECO:0000269|PubMed:9407116}.
CC   -!- INTERACTION:
CC       P11274; P62993: GRB2; NbExp=9; IntAct=EBI-712838, EBI-401755;
CC       P11274; Q6ZV89-1: SH2D5; NbExp=2; IntAct=EBI-712838, EBI-15101685;
CC       P11274; Q9H2K2: TNKS2; NbExp=3; IntAct=EBI-712838, EBI-4398527;
CC       P11274; A2AM67: Sh2d5; Xeno; NbExp=7; IntAct=EBI-712838, EBI-15101945;
CC       P11274; Q8JZW5: Sh2d5; Xeno; NbExp=2; IntAct=EBI-712838, EBI-15101675;
CC       P11274-1; P18031: PTPN1; NbExp=3; IntAct=EBI-8658094, EBI-968788;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic density
CC       {ECO:0000250|UniProtKB:Q6PAJ1}. Cell projection, dendritic spine
CC       {ECO:0000250|UniProtKB:Q6PAJ1}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q6PAJ1}. Synapse {ECO:0000250|UniProtKB:F1LXF1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11274-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11274-2; Sequence=VSP_024352;
CC   -!- DOMAIN: The region involved in binding to ABL1 SH2-domain is rich in
CC       serine residues and needs to be Ser/Thr phosphorylated prior to SH2
CC       binding. This region is essential for the activation of the ABL1
CC       tyrosine kinase and transforming potential of the chimeric BCR-ABL
CC       oncogene.
CC   -!- DOMAIN: The DH domain is involved in interaction with CCPG1.
CC       {ECO:0000250|UniProtKB:Q6PAJ1}.
CC   -!- DOMAIN: The amino terminus contains an intrinsic kinase activity. The
CC       central Dbl homology (DH) domain functions as guanine nucleotide
CC       exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1.
CC       Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to
CC       the GTP-bound form. The C-terminus is a Rho-GAP domain which stimulates
CC       GTP hydrolysis by RAC1, RAC2 and CDC42. The protein has a unique
CC       structure having two opposing regulatory activities toward small GTP-
CC       binding proteins. {ECO:0000305|PubMed:7479768}.
CC   -!- PTM: Autophosphorylated. Phosphorylated by FES/FPS on tyrosine
CC       residues, leading to down-regulation of the BCR kinase activity.
CC       Phosphorylation at Tyr-177 by HCK is important for interaction with
CC       GRB2. {ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:9407116}.
CC   -!- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal
CC       myeloproliferative disorder of a pluripotent stem cell with a specific
CC       cytogenetic abnormality, the Philadelphia chromosome (Ph), involving
CC       myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-
CC       lymphoid cells, but not marrow fibroblasts.
CC       {ECO:0000269|PubMed:2407300, ECO:0000269|PubMed:3107980,
CC       ECO:0000269|PubMed:3540951}. Note=The gene represented in this entry is
CC       involved in disease pathogenesis.
CC   -!- DISEASE: Note=A chromosomal aberration involving BCR has been found in
CC       patients with chronic myeloid leukemia. Translocation t(9;22)(q34;q11)
CC       with ABL1. The translocation produces a BCR-ABL found also in acute
CC       myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
CC       {ECO:0000269|PubMed:3107980, ECO:0000269|PubMed:7665185}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06073.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BCRID55.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00661; CAA68676.1; -; mRNA.
DR   EMBL; U07000; AAB60388.1; -; Genomic_DNA.
DR   EMBL; AB209991; BAE06073.1; ALT_INIT; mRNA.
DR   EMBL; X02596; CAA26441.1; -; mRNA.
DR   EMBL; M15025; AAA35594.1; -; Genomic_DNA.
DR   EMBL; X52828; CAA37010.1; -; Genomic_DNA.
DR   EMBL; X52829; CAA37011.1; -; Genomic_DNA.
DR   EMBL; X14676; CAA32806.1; -; mRNA.
DR   EMBL; M64437; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13806.1; -. [P11274-1]
DR   CCDS; CCDS13807.1; -. [P11274-2]
DR   PIR; A26664; TVHUA2.
DR   PIR; A91064; TVHUBR.
DR   RefSeq; NP_004318.3; NM_004327.3. [P11274-1]
DR   RefSeq; NP_067585.2; NM_021574.2. [P11274-2]
DR   PDB; 1K1F; X-ray; 2.20 A; A/B/C/D/E/F/G/H=1-72.
DR   PDB; 2AIN; NMR; -; B=1266-1271.
DR   PDB; 5N6R; NMR; -; A=487-702.
DR   PDB; 5N7E; X-ray; 1.65 A; B=487-702.
DR   PDB; 5OC7; X-ray; 1.65 A; A/D=704-893.
DR   PDBsum; 1K1F; -.
DR   PDBsum; 2AIN; -.
DR   PDBsum; 5N6R; -.
DR   PDBsum; 5N7E; -.
DR   PDBsum; 5OC7; -.
DR   AlphaFoldDB; P11274; -.
DR   SASBDB; P11274; -.
DR   SMR; P11274; -.
DR   BioGRID; 107083; 139.
DR   ELM; P11274; -.
DR   IntAct; P11274; 139.
DR   MINT; P11274; -.
DR   STRING; 9606.ENSP00000303507; -.
DR   BindingDB; P11274; -.
DR   ChEMBL; CHEMBL5146; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugCentral; P11274; -.
DR   GlyGen; P11274; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P11274; -.
DR   MetOSite; P11274; -.
DR   PhosphoSitePlus; P11274; -.
DR   BioMuta; BCR; -.
DR   DMDM; 143811366; -.
DR   EPD; P11274; -.
DR   jPOST; P11274; -.
DR   MassIVE; P11274; -.
DR   MaxQB; P11274; -.
DR   PaxDb; P11274; -.
DR   PeptideAtlas; P11274; -.
DR   PRIDE; P11274; -.
DR   ProteomicsDB; 52729; -. [P11274-1]
DR   ProteomicsDB; 52730; -. [P11274-2]
DR   Antibodypedia; 9277; 674 antibodies from 39 providers.
DR   DNASU; 613; -.
DR   Ensembl; ENST00000305877.13; ENSP00000303507.8; ENSG00000186716.21. [P11274-1]
DR   Ensembl; ENST00000359540.7; ENSP00000352535.3; ENSG00000186716.21. [P11274-2]
DR   GeneID; 613; -.
DR   KEGG; hsa:613; -.
DR   MANE-Select; ENST00000305877.13; ENSP00000303507.8; NM_004327.4; NP_004318.3.
DR   UCSC; uc002zww.4; human. [P11274-1]
DR   CTD; 613; -.
DR   DisGeNET; 613; -.
DR   GeneCards; BCR; -.
DR   HGNC; HGNC:1014; BCR.
DR   HPA; ENSG00000186716; Tissue enhanced (brain).
DR   MalaCards; BCR; -.
DR   MIM; 151410; gene.
DR   MIM; 608232; phenotype.
DR   neXtProt; NX_P11274; -.
DR   OpenTargets; ENSG00000186716; -.
DR   Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2).
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 261330; Distal 22q11.2 microdeletion syndrome.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA25321; -.
DR   VEuPathDB; HostDB:ENSG00000186716; -.
DR   eggNOG; KOG4269; Eukaryota.
DR   GeneTree; ENSGT00940000153491; -.
DR   HOGENOM; CLU_004164_0_0_1; -.
DR   InParanoid; P11274; -.
DR   OMA; EKSYNRT; -.
DR   OrthoDB; 762492at2759; -.
DR   PhylomeDB; P11274; -.
DR   TreeFam; TF105082; -.
DR   PathwayCommons; P11274; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   SignaLink; P11274; -.
DR   SIGNOR; P11274; -.
DR   BioGRID-ORCS; 613; 32 hits in 1118 CRISPR screens.
DR   ChiTaRS; BCR; human.
DR   EvolutionaryTrace; P11274; -.
DR   GeneWiki; BCR_(gene); -.
DR   GenomeRNAi; 613; -.
DR   Pharos; P11274; Tclin.
DR   PRO; PR:P11274; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P11274; protein.
DR   Bgee; ENSG00000186716; Expressed in nucleus accumbens and 180 other tissues.
DR   ExpressionAtlas; P11274; baseline and differential.
DR   Genevisible; P11274; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0048041; P:focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:0048872; P:homeostasis of number of cells; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0065002; P:intracellular protein transmembrane transport; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:1905517; P:macrophage migration; IEA:Ensembl.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISS:UniProtKB.
DR   GO; GO:0060313; P:negative regulation of blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0002692; P:negative regulation of cellular extravasation; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:1905522; P:negative regulation of macrophage migration; IEA:Ensembl.
DR   GO; GO:0043314; P:negative regulation of neutrophil degranulation; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0060268; P:negative regulation of respiratory burst; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0051171; P:regulation of nitrogen compound metabolic process; IEA:Ensembl.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0043114; P:regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IMP:UniProtKB.
DR   CDD; cd00160; RhoGEF; 1.
DR   Gene3D; 1.10.555.10; -; 1.
DR   Gene3D; 1.20.900.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 4.10.280.30; -; 1.
DR   InterPro; IPR037769; Abr/Bcr.
DR   InterPro; IPR015123; Bcr-Abl_oncoprot_oligo.
DR   InterPro; IPR036481; Bcr-Abl_oncoprot_oligo_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   PANTHER; PTHR23182; PTHR23182; 1.
DR   Pfam; PF09036; Bcr-Abl_Oligo; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SUPFAM; SSF48065; SSF48065; 1.
DR   SUPFAM; SSF48350; SSF48350; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF69036; SSF69036; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50238; RHOGAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell projection; Chromosomal rearrangement; Coiled coil; GTPase activation;
KW   Guanine-nucleotide releasing factor; Kinase; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Synapse; Transferase.
FT   CHAIN           1..1271
FT                   /note="Breakpoint cluster region protein"
FT                   /id="PRO_0000080933"
FT   DOMAIN          498..691
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          708..866
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          893..1020
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          1054..1248
FT                   /note="Rho-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00172"
FT   REGION          1..426
FT                   /note="Kinase"
FT   REGION          67..173
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          185..247
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          197..385
FT                   /note="Binding to ABL SH2-domain"
FT   REGION          286..392
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          416..476
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          28..55
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        198..222
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        330..385
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            426..427
FT                   /note="Breakpoint for translocation to form BCR-ABL
FT                   oncogene"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         122
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         177
FT                   /note="Phosphotyrosine; by HCK"
FT                   /evidence="ECO:0000269|PubMed:9407116,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         202
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         236
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAJ1"
FT   MOD_RES         246
FT                   /note="Phosphotyrosine; by FES"
FT                   /evidence="ECO:0000269|PubMed:15302586"
FT   MOD_RES         356
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAJ1"
FT   MOD_RES         385
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAJ1"
FT   MOD_RES         459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         463
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         471
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAJ1"
FT   MOD_RES         473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         488
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         554
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         641
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         644
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         693
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         894
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1264
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:19690332"
FT   VAR_SEQ         961..1004
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:3285291"
FT                   /id="VSP_024352"
FT   VARIANT         400
FT                   /note="S -> P (in a bladder transitional cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041883"
FT   VARIANT         413
FT                   /note="I -> M (in dbSNP:rs56321828)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041884"
FT   VARIANT         558
FT                   /note="K -> T (in dbSNP:rs4437065)"
FT                   /id="VAR_051983"
FT   VARIANT         752
FT                   /note="D -> E (in dbSNP:rs12484731)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041885"
FT   VARIANT         796
FT                   /note="N -> S (in dbSNP:rs140504)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:2407300, ECO:0000269|PubMed:3107980,
FT                   ECO:0000269|PubMed:3285291, ECO:0000269|Ref.3"
FT                   /id="VAR_031552"
FT   VARIANT         910
FT                   /note="Y -> C (in dbSNP:rs35537221)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041886"
FT   VARIANT         949
FT                   /note="V -> I (in dbSNP:rs2229038)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041887"
FT   VARIANT         1037
FT                   /note="E -> K (in dbSNP:rs776552570)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_031553"
FT   VARIANT         1091
FT                   /note="V -> M (in dbSNP:rs778229520)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041888"
FT   VARIANT         1096
FT                   /note="T -> A (in dbSNP:rs745459086)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041889"
FT   VARIANT         1104
FT                   /note="A -> G (in dbSNP:rs11558696)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041890"
FT   VARIANT         1106
FT                   /note="D -> N (in dbSNP:rs879255379)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041891"
FT   VARIANT         1127
FT                   /note="T -> M (in dbSNP:rs35812689)"
FT                   /id="VAR_031554"
FT   VARIANT         1149
FT                   /note="A -> T (in dbSNP:rs200099830)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041892"
FT   VARIANT         1161
FT                   /note="E -> K"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041893"
FT   VARIANT         1187
FT                   /note="K -> E (in dbSNP:rs1195127922)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041894"
FT   VARIANT         1189
FT                   /note="V -> M (in dbSNP:rs55816482)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041895"
FT   VARIANT         1204
FT                   /note="A -> G (in dbSNP:rs56265970)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041896"
FT   VARIANT         1235
FT                   /note="W -> R (in dbSNP:rs55719322)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041897"
FT   MUTAGEN         177
FT                   /note="Y->F: Abolishes interaction with FES and GRB2."
FT                   /evidence="ECO:0000269|PubMed:15302586,
FT                   ECO:0000269|PubMed:9407116"
FT   MUTAGEN         689..690
FT                   /note="NE->AA: Loss of RHOAGEF activity."
FT                   /evidence="ECO:0000269|PubMed:23940119"
FT   MUTAGEN         1090
FT                   /note="R->A: Loss of GAP activity. Loss of GAP activity;
FT                   when associated with A-1202."
FT                   /evidence="ECO:0000269|PubMed:17116687"
FT   MUTAGEN         1202
FT                   /note="N->A: Loss of GAP activity; when associated with
FT                   A-1090."
FT                   /evidence="ECO:0000269|PubMed:17116687"
FT   MUTAGEN         1269..1271
FT                   /note="Missing: Abolishes interaction with PDZK1."
FT                   /evidence="ECO:0000269|PubMed:15494376"
FT   MUTAGEN         1271
FT                   /note="V->A: Reduces interaction with PDZK1. Abolishes
FT                   interaction with DLG4. No effect on synaptic localization."
FT                   /evidence="ECO:0000269|PubMed:15494376,
FT                   ECO:0000269|PubMed:20962234"
FT   CONFLICT        287
FT                   /note="M -> I (in Ref. 1; CAA68676)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        418
FT                   /note="G -> D (in Ref. 1; CAA68676)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        483
FT                   /note="E -> K (in Ref. 1; CAA68676)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        560
FT                   /note="F -> S (in Ref. 1; CAA68676)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        690
FT                   /note="E -> D (in Ref. 11)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        733
FT                   /note="D -> E (in Ref. 4; CAA26441)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..14
FT                   /evidence="ECO:0007829|PDB:1K1F"
FT   HELIX           28..64
FT                   /evidence="ECO:0007829|PDB:1K1F"
FT   HELIX           492..521
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           524..531
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   STRAND          533..535
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           540..546
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   TURN            547..549
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           550..569
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           578..586
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           588..611
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           613..618
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   STRAND          630..634
FT                   /evidence="ECO:0007829|PDB:5N6R"
FT   HELIX           639..651
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           653..661
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   HELIX           670..687
FT                   /evidence="ECO:0007829|PDB:5N7E"
FT   STRAND          694..697
FT                   /evidence="ECO:0007829|PDB:5N6R"
FT   STRAND          709..719
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          722..740
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          751..758
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   HELIX           759..761
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          762..767
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          830..838
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          843..847
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   HELIX           851..865
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   HELIX           876..885
FT                   /evidence="ECO:0007829|PDB:5OC7"
FT   STRAND          1268..1271
FT                   /evidence="ECO:0007829|PDB:2AIN"
SQ   SEQUENCE   1271 AA;  142819 MW;  4BF66FA1E9D205FE CRC64;
     MVDPVGFAEA WKAQFPDSEP PRMELRSVGD IEQELERCKA SIRRLEQEVN QERFRMIYLQ
     TLLAKEKKSY DRQRWGFRRA AQAPDGASEP RASASRPQPA PADGADPPPA EEPEARPDGE
     GSPGKARPGT ARRPGAAASG ERDDRGPPAS VAALRSNFER IRKGHGQPGA DAEKPFYVNV
     EFHHERGLVK VNDKEVSDRI SSLGSQAMQM ERKKSQHGAG SSVGDASRPP YRGRSSESSC
     GVDGDYEDAE LNPRFLKDNL IDANGGSRPP WPPLEYQPYQ SIYVGGMMEG EGKGPLLRSQ
     STSEQEKRLT WPRRSYSPRS FEDCGGGYTP DCSSNENLTS SEEDFSSGQS SRVSPSPTTY
     RMFRDKSRSP SQNSQQSFDS SSPPTPQCHK RHRHCPVVVS EATIVGVRKT GQIWPNDGEG
     AFHGDADGSF GTPPGYGCAA DRAEEQRRHQ DGLPYIDDSP SSSPHLSSKG RGSRDALVSG
     ALESTKASEL DLEKGLEMRK WVLSGILASE ETYLSHLEAL LLPMKPLKAA ATTSQPVLTS
     QQIETIFFKV PELYEIHKEF YDGLFPRVQQ WSHQQRVGDL FQKLASQLGV YRAFVDNYGV
     AMEMAEKCCQ ANAQFAEISE NLRARSNKDA KDPTTKNSLE TLLYKPVDRV TRSTLVLHDL
     LKHTPASHPD HPLLQDALRI SQNFLSSINE EITPRRQSMT VKKGEHRQLL KDSFMVELVE
     GARKLRHVFL FTDLLLCTKL KKQSGGKTQQ YDCKWYIPLT DLSFQMVDEL EAVPNIPLVP
     DEELDALKIK ISQIKNDIQR EKRANKGSKA TERLKKKLSE QESLLLLMSP SMAFRVHSRN
     GKSYTFLISS DYERAEWREN IREQQKKCFR SFSLTSVELQ MLTNSCVKLQ TVHSIPLTIN
     KEDDESPGLY GFLNVIVHSA TGFKQSSNLY CTLEVDSFGY FVNKAKTRVY RDTAEPNWNE
     EFEIELEGSQ TLRILCYEKC YNKTKIPKED GESTDRLMGK GQVQLDPQAL QDRDWQRTVI
     AMNGIEVKLS VKFNSREFSL KRMPSRKQTG VFGVKIAVVT KRERSKVPYI VRQCVEEIER
     RGMEEVGIYR VSGVATDIQA LKAAFDVNNK DVSVMMSEMD VNAIAGTLKL YFRELPEPLF
     TDEFYPNFAE GIALSDPVAK ESCMLNLLLS LPEANLLTFL FLLDHLKRVA EKEAVNKMSL
     HNLATVFGPT LLRPSEKESK LPANPSQPIT MTDSWSLEVM SQVQVLLYFL QLEAIPAPDS
     KRQSILFSTE V
//
